Nahdi Stock Trading: Everything You Need to Know About Performance and

Nahdi Medical Company is one of the largest and most renowned pharmacy chains in Saudi Arabia. Founded in the 1980s, it has gradually expanded to operate over 1,300 pharmacies across all regions and major cities. Nahdi’s activities include the sale of medicines, medical supplies, health and personal care products, as well as providing certain direct health services such as blood pressure and glucose measurement. The company has earned a leading position thanks to its wide geographic presence and advanced services.

Nahdi’s significance in the Saudi financial market lies in being the first local pharmacy entity of this scale to be listed on the stock market (Tadawul), providing investors with direct exposure to the defensive healthcare sector. Nahdi represents a model of stability and growth, and its stock serves as an indicator of the private healthcare sector’s health in the Kingdom. With its listing, Nahdi has become more transparent in its financial results and expansion plans, strengthening its stock’s position in investment portfolios aiming for sector diversification and risk mitigation against economic fluctuations.

The Saudi financial market witnessed a significant event in 2021 when Nahdi Medical announced its initial public offering, becoming one of the first pharmacy companies listed on Tadawul. The IPO was priced at SAR 35 per share and attracted strong demand from both retail and institutional investors, reflecting market confidence in the company’s performance and the healthcare sector’s prospects.

After listing, Nahdi’s share price fluctuated with market factors, rising to SAR 70–75 in the initial months before stabilizing in the SAR 55–60 range by 2025. This trajectory reflects market reactions to the company’s results, sector developments, and available liquidity. Today, Nahdi’s stock is viewed as one of the defensive stocks with a relatively high valuation, making it a constant focus for analysts and observers of healthcare companies’ performance.

Nahdi’s stock belongs to the healthcare and pharmacy sector, which continues to see steady growth in Saudi Arabia. The pharmacy sector is characterized by stable and growing demand for medicines and health products, driven by population growth, rising average age, and increased government spending on healthcare as part of Vision 2030.

Companies in this sector face regulatory challenges, with the Saudi Food and Drug Authority imposing strict controls to ensure product quality and consumer safety. Competition is intense among major chains such as Nahdi, Al-Dawaa, and White Pharmacy, as well as small retailers and government-affiliated pharmacies. Competition centers on service quality, location, and product variety. The sector is also undergoing rapid digital transformation, with rising demand for online services and home delivery of medicines—a trend in which Nahdi has invested significantly.

The latest available financial data indicates that Nahdi achieved revenues of approximately SAR 3.0 billion in 2024, representing nearly 10% growth over the previous year. Annual net profit reached around SAR 370 million, maintaining a moderate profit margin that reflects operational efficiency and cost control.

Preliminary forecasts for 2025 suggest continued moderate growth, with potential revenue increases of 8–12%, driven by branch expansion and digital platform development. Nahdi employs over 7,000 staff, supporting its Saudization strategy and contribution to the national economy. Its market share stands at about 35–40% of total pharmacy sales in the Kingdom, confirming Nahdi’s leadership in the Saudi pharmacy sector.

Nahdi’s share is currently trading in the SAR 55–60 range (early 2025), after notable volatility since its listing. This price reflects investor confidence in the company’s ability to achieve sustainable growth and places it among mid-cap stocks on Tadawul.

Based on this price and the number of outstanding shares, Nahdi’s market capitalization is estimated at SAR 22–24 billion. This growth in market value over the past two years is the result of positive financial performance, a broader investor base, and increased institutional liquidity in the stock. The share price’s stability at these levels signals market maturity in evaluating healthcare companies, considering growth prospects and risks related to competition and regulation.

One of the key financial indicators monitored by investors is the price-to-earnings (P/E) ratio, which represents the share price relative to annual earnings per share. Nahdi’s P/E at the start of 2025 stands at around 30–40 times, higher than the market average, reflecting investor optimism for continued profit growth.

This elevated valuation is explained by the demand for healthcare stocks, which are considered relatively safe havens during economic volatility. However, a high P/E also means investors expect the current growth rate to continue; if these expectations are not met, the stock may undergo a revaluation or price correction. This highlights the importance of closely monitoring quarterly results and the company’s strategic policies.

Up to the end of 2024, Nahdi has not announced any cash dividend distributions to shareholders. The management currently prefers to reinvest profits in geographic expansion, opening new branches, and developing digital channels and modern services. This strategy aims to enhance long-term growth and increase the company’s market value.

With stable cash flows and higher profitability in the future, Nahdi may consider dividend distributions, especially after completing major expansion plans. This decision depends on several factors, including the company’s growth policy, liquidity levels, and board directives. It is important for investors to follow the company’s official announcements regarding future dividend policies.

Nahdi faces strong competition from several companies and pharmacy chains, most notably Al-Dawaa Group and White Pharmacy. These companies have extensive distribution networks and offer products and services similar to Nahdi, compelling the latter to continually improve service quality and provide competitive advantages to customers.

In addition to major chains, there are numerous local pharmacies and large retailers offering health products. Some government and charitable hospitals also provide pharmaceutical services free or at subsidized prices, representing a form of indirect competition. Competition is also prominent in digital channels, as each company seeks to develop its apps and online services to attract customers who prefer remote ordering.

Nahdi maintains its market leadership through ongoing investment in infrastructure, expansion into new areas, and diversification of health products and services.

Recent years have witnessed significant changes in Saudi consumer behavior, with a growing trend towards online shopping and ordering medicines via the internet. Nahdi responded to this shift by developing its digital platform and mobile applications, streamlining online ordering and fast delivery.

These steps have doubled the company’s digital sales and provided a new growth channel beyond the geographic constraints of traditional branches. Partnerships with other digital platforms have also expanded Nahdi’s reach, especially in remote cities or neighborhoods lacking easy access to conventional pharmacies.

E-commerce is a core element in Nahdi’s future growth strategy, and the company continues to invest in enhancing user experience and building trust in digital health services.

Throughout 2024, Nahdi continued to execute its geographic expansion plans, opening dozens of new branches, particularly in remote and secondary cities lacking comprehensive pharmacy services. This strategy aims to increase the company’s market share, broaden its customer base, and improve healthcare coverage in the Kingdom.

Alongside branch expansion, Nahdi is strengthening partnerships with medical centers and both public and private hospitals, and developing training programs for Saudi talent as part of Saudization plans. The company also periodically explores acquisition or merger opportunities with smaller entities to enhance operational strength and expand its service portfolio.

These expansions reflect Nahdi’s commitment to supporting Vision 2030 goals of improving healthcare quality and boosting the national economy.

Since early 2024, Nahdi has announced several important developments, most notably continued branch expansion, digital platform development, and forming strategic partnerships with medical and healthcare institutions. Quarterly financial results have shown notable growth in revenue and net profit, supported by improved operational efficiency and rising demand for health products.

Nahdi has participated in national initiatives aligned with Saudi Vision 2030, such as providing subsidized medicines and localizing jobs in the healthcare sector. The company has also focused on improving its supply chain by establishing advanced warehouses and adopting sophisticated inventory management and fast delivery systems.

These developments underscore Nahdi’s commitment to reinforcing its leadership in the pharmacy sector and continuing to deliver innovative solutions that meet the expectations of customers and the Saudi healthcare industry.

Nahdi’s stock performance is influenced by several key factors, most notably the company’s financial results, expansion strategies, market competition, and regulatory developments in the pharmacy sector. General economic changes and individual income levels also play an indirect role in demand for the company’s products.

The healthcare sector in the Kingdom is expected to continue growing, driven by increased public and private spending and rising health awareness in society. Digital trends and the shift towards e-commerce are additional growth drivers for Nahdi. However, risks related to competition and regulatory changes remain, requiring the company to continually develop its services and improve operational efficiency.

Investors closely monitor the company’s announcements and quarterly results to assess Nahdi’s ability to achieve its goals and enhance shareholder value.

To obtain official and reliable information about Nahdi stock and its developments in the Saudi stock market, it is recommended to refer to several main sources:

- The official website of the Saudi Stock Exchange (Tadawul), which provides daily share prices, financial indicators, and quarterly reports.
- The official website of Nahdi Medical Company, which publishes annual reports and management and strategic developments.
- Specialized economic news platforms such as Argaam, Al Arabiya Net, and Al Eqtisadiah, which offer comprehensive coverage of Saudi companies’ news.
- Global financial analysis platforms such as Investing, Reuters, and Bloomberg, which provide analyses and comparisons of stock performance.

It is always advisable to compare information from multiple sources and follow the company’s official announcements for the latest developments and accurate data on Nahdi stock.